Serum nesfatin-1 levels in overt and subclinical hyperthyroidism

Minerva Endocrinol. 2014 Sep;39(3):209-14.

Abstract

Aim: Nesfatin-1 was recently discovered anorexigenic peptide in the brain which is derived from nucleobindin-2. Central and peripheral administration of nesfatin-1, inhibits food intake, dose-dependently. Hyperthyroid patients have increased appetite and food intake with a craving for carbohydrate-rich food, at the beginning of disease, but the physiological mechanisms underlying this behavior is not known exactly. In this study, we investigated whether nesfatin-1 is involved in the regulation of appetite and body weight in hyperthyroidism, or not.

Methods: A total of 70 patients with subclinical (35) and overt hyperthyroidism (35) compared with 35 control patients. Serum nesfatin-1 level was measured from all samples by commercial ELISA kit.

Results: Serum nesfatin-1 levels were similar between three groups (P=0.293). After adjusting for age and body mass index, nesfatin-1 levels in control group was not different from subclinical and overt hyperthyroid group, respectively (P=0.567 and P=0.519).

Conclusion: These data showed that serum nesfatin-1 levels do not significant change in overt and subclinical hyperthyroidism.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Appetite / physiology*
  • Blood Glucose / analysis
  • Body Mass Index
  • Body Weight / physiology*
  • Calcium-Binding Proteins / blood*
  • Creatine / blood
  • DNA-Binding Proteins / blood*
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Hyperthyroidism / blood*
  • Male
  • Middle Aged
  • Nerve Tissue Proteins / blood*
  • Nucleobindins
  • Thyroid Hormones / blood
  • Thyrotropin / blood
  • Weight Loss
  • Young Adult

Substances

  • Blood Glucose
  • Calcium-Binding Proteins
  • DNA-Binding Proteins
  • NUCB2 protein, human
  • Nerve Tissue Proteins
  • Nucleobindins
  • Thyroid Hormones
  • Thyrotropin
  • Creatine